• Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy.

Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy.

Annals of internal medicine (2009-11-04)
Sophia Zoungas, Toshiharu Ninomiya, Rachel Huxley, Alan Cass, Meg Jardine, Martin Gallagher, Anushka Patel, Ali Vasheghani-Farahani, Gelareh Sadigh, Vlado Perkovic

Intravenous sodium bicarbonate has been proposed to reduce the risk for contrast-induced nephropathy (CIN). To determine the effect of sodium bicarbonate on the risk for CIN. MEDLINE, PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials from 1950 to December 2008; conference proceedings; and, without language restriction. Randomized, controlled trials of intravenous sodium bicarbonate that prespecified the outcome of CIN as a 25% increase in baseline serum creatinine level or an absolute increase of 44 micromol/L (0.5 mg/dL) after radiocontrast administration. Using standardized protocols, 2 reviewers serially abstracted data for each study. 23 published and unpublished trials with information on 3563 patients and 396 CIN events were included. The pooled relative risk was 0.62 (95% CI, 0.45 to 0.86), with evidence of significant heterogeneity across studies (I(2) = 49.1%; P = 0.004). Some heterogeneity was due to the difference in the estimates between published and unpublished studies: relative risk, 0.43 (CI, 0.25 to 0.75) versus 0.78 (CI, 0.52 to 1.17), respectively. Meta-regression showed that small, poor-quality studies that assessed outcomes soon after radiocontrast administration were more likely to suggest benefit (P < 0.05 for all). No clear effects of treatment on the risk for dialysis, heart failure, and total mortality were identified. Power to assess clinical end points was limited. The effectiveness of sodium bicarbonate treatment to prevent CIN in high-risk patients remains uncertain. Earlier reports probably overestimated the magnitude of any benefit, whereas larger, more recent trials have had neutral results. Large multicenter trials are required to clarify whether sodium bicarbonate has value for prevention of CIN before routine use can be recommended. None.

Product Number
Product Description

Sodium bicarbonate solution, solution (7.5%), sterile-filtered, BioReagent, suitable for cell culture
Sodium bicarbonate, powder, BioReagent, for molecular biology, suitable for cell culture, suitable for insect cell culture
Sodium bicarbonate-12C, 99.9 atom % 12C
Sodium bicarbonate, ReagentPlus®, ≥99.5%, powder
Sodium bicarbonate, anhydrous, free-flowing, Redi-Dri, ReagentPlus®, ≥99.5%
Sodium hydrogencarbonate, −40-+140 mesh, ≥95%
Sodium bicarbonate concentrate, 0.1 M NaHCO3 in water, eluent concentrate for IC
Sodium bicarbonate, tested according to Ph. Eur.
Sodium bicarbonate, BioXtra, 99.5-100.5%
Sodium bicarbonate, United States Pharmacopeia (USP) Reference Standard
Sodium bicarbonate, ACS reagent, ≥99.7%
Sodium bicarbonate, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, E500, 99.0-100.5%, powder